<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4676">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046056</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-419-4015</org_study_id>
    <secondary_id>2016-003179-23</secondary_id>
    <nct_id>NCT03046056</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of filgotinib, when compared
      to placebo, in establishing clinical remission in participants with Crohn's disease
      involving the small bowel. Participants will have the option to enter a separate long-term
      extension study if they meet eligibility requirements.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Achieving Clinical Remission at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Magnetic Resonance Imaging (MRI) disease parameters at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving Small Bowel Remission Measured via MRI Disease Parameters at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving Remission in the Terminal Ileum Measured via MRI Disease Parameters at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving Remission in all Bowel Segments via MRI Disease Parameters at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Reported Symptoms of Abdominal Pain and Liquid Stool Frequency at Week 10</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient Reported Symptoms of Abdominal Pain and Liquid Stool Frequency at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Small Bowel Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Filgotinib Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib dose A + placebo to match filgotinib dose B for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgotinib Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib dose B + placebo to match filgotinib dose A for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match filgotinib dose A + placebo to match filgotinib dose B for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Filgotinib Dose A</arm_group_label>
    <arm_group_label>Filgotinib Dose B</arm_group_label>
    <other_name>GS-6034</other_name>
    <other_name>GLPG0634</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match filgotinib</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Filgotinib Dose A</arm_group_label>
    <arm_group_label>Filgotinib Dose B</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Males or non-pregnant, nonlactating females, ages 18 to 75 years, inclusive based on
             the date of screening visit

          -  Moderately or severely active CD

          -  Minimum duration of CD of at least 6 months

          -  Presence of diseased SB segments in at least 1 of the following segments: terminal
             ileum, distal ileum, or jejunum

          -  Patients with additional colonic involvement of CD are permitted in study as long as
             SBCD is present

          -  Previously demonstrated an inadequate clinical response, loss of response to, or
             intolerance to at least 1 of the following agents (depending on current country
             treatment recommendations/guidelines):

               -  Corticosteroids

               -  Immunomodulators

               -  Tumor necrosis factor-alpha (TNFÎ±) antagonists

               -  Vedolizumab

          -  Willing and able to undergo magnetic resonance enterography (MRE) per protocol
             requirements

        Key Exclusion Criteria:

          -  Presence of symptomatic or clinically significant (eg, obstructive or symptomatic)
             strictures or stenosis.

          -  Presence of fistulae

          -  Evidence of short bowel syndrome

          -  Presence of ulcerative colitis, indeterminate colitis, ischemic colitis, fulminant
             colitis, or toxic mega-colon

          -  History of total colectomy, hemi-colectomy, presence of ileostomy or colostomy, or
             likely requirement for surgery during the study

          -  Use of any prohibited concomitant medications as described in the study protocol

          -  Active tuberculosis (TB) or history of latent TB that has not been treated

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>419-4015study@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastroenterology Center of the MidSouth</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Consultants</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 6, 2017</lastchanged_date>
  <firstreceived_date>February 6, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
